Terms: = Ovarian cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Diagnosis
13 results:
1. Clinical and multiparametric MRI features for differentiating uterine carcinosarcoma from endometrioid adenocarcinoma.
Chen X; Guo Q; Chen X; Zheng W; Kang Y; Cao D
BMC Med Imaging; 2024 Feb; 24(1):48. PubMed ID: 38373912
[TBL] [Abstract] [Full Text] [Related]
2. Endometrioid adenocarcinoma: combined multiparametric MRI and tumour marker HE4 to evaluate tumour grade and lymphovascular space invasion.
Yue XN; He XY; Wu JJ; Fan W; Zhang HJ; Wang CW
Clin Radiol; 2023 Aug; 78(8):e574-e581. PubMed ID: 37183140
[TBL] [Abstract] [Full Text] [Related]
3. Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.
Zhang Z; Wang J; Wu X; Liu Y; Xi X
J Obstet Gynaecol Res; 2022 Aug; 48(8):2180-2188. PubMed ID: 35778826
[TBL] [Abstract] [Full Text] [Related]
4. Utilization and Treatment Patterns of Cytoreduction Surgery and Intraperitoneal Chemotherapy in the United States.
Ellis RJ; Schlick CJR; Yang AD; Barber EL; Bilimoria KY; Merkow RP
Ann Surg Oncol; 2020 Jan; 27(1):214-221. PubMed ID: 31187369
[TBL] [Abstract] [Full Text] [Related]
5. Challenges and controversies in the conservative management of uterine and ovarian cancer.
Janda M; McGrath S; Obermair A
Best Pract Res Clin Obstet Gynaecol; 2019 Feb; 55():93-108. PubMed ID: 30243603
[TBL] [Abstract] [Full Text] [Related]
6. Deubiquitinases and the new therapeutic opportunities offered to cancer.
Pfoh R; Lacdao IK; Saridakis V
Endocr Relat Cancer; 2015 Feb; 22(1):T35-54. PubMed ID: 25605410
[TBL] [Abstract] [Full Text] [Related]
7. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract] [Full Text] [Related]
8. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
Mhawech-Fauceglia P; Herrmann FR; Rai H; Tchabo N; Lele S; Izevbaye I; Odunsi K; Cheney RT
Am J Clin Pathol; 2010 Jun; 133(6):899-908. PubMed ID: 20472848
[TBL] [Abstract] [Full Text] [Related]
9. ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.
Kobayashi H
Int J Clin Oncol; 2009 Oct; 14(5):378-82. PubMed ID: 19856043
[TBL] [Abstract] [Full Text] [Related]
10. Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature.
Akbulut M; Tosun H; Soysal ME; Oztekin O
Arch Gynecol Obstet; 2008 Jul; 278(1):79-84. PubMed ID: 18066564
[TBL] [Abstract] [Full Text] [Related]
11. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract] [Full Text] [Related]
12. Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.
Ohishi Y; Kaku T; Kaneki E; Wake N; Tsuneyoshi M
Gynecol Oncol; 2007 May; 105(2):548-52. PubMed ID: 17341430
[TBL] [Abstract] [Full Text] [Related]
13. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas.
Ramalingam P; Malpica A; Silva EG; Gershenson DM; Liu JL; Deavers MT
Am J Surg Pathol; 2004 Nov; 28(11):1499-505. PubMed ID: 15489654
[TBL] [Abstract] [Full Text] [Related]
